Back to Search Start Over

Prognostic factors among patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: A retrospective cohort study using a nationwide inpatient database in Japan.

Authors :
Myojin S
Michihata N
Shoji K
Takanashi JI
Matsui H
Fushimi K
Miyairi I
Yasunaga H
Source :
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy [J Infect Chemother] 2023 Jun; Vol. 29 (6), pp. 610-614. Date of Electronic Publication: 2023 Mar 04.
Publication Year :
2023

Abstract

Introduction: Shiga toxin-producing Escherichia coli (STEC) causes hemorrhagic colitis and hemolytic uremic syndrome (STEC-HUS). Understanding its prognostic factors is essential for immediate interventions. We examined early-phase unfavorable prognostic factors among patients with STEC-HUS using a nationwide database.<br />Material and Methods: This is a retrospective cohort study to analyze practice patterns and identify prognostic factors among patients with STEC-HUS. We used the Diagnosis Procedure Combination Database, which includes approximately half of the acute-care hospitalized patients in Japan. We enrolled patients who were hospitalized for STEC-HUS from July 2010 to March 2020. The composite unfavorable outcome included in-hospital death, mechanical ventilation, dialysis, and rehabilitation at discharge. Unfavorable prognostic factors were assessed using a multivariable logistic regression model.<br />Results: We included 615 patients with STEC-HUS (median age, 7 years). Of them, 30 (4.9%) patients had acute encephalopathy and 24 (3.9%) died within 3 months of admission. Unfavorable composite outcome was observed in 124 (20.2%) patients. Significant unfavorable prognostic factors were age of 18 years or older, methylprednisolone pulse therapy, antiepileptic drug administration, and respiratory support within 2 days of admission.<br />Discussion: Patients requiring early steroid pulse therapy, antiepileptic drugs, and respiratory support were considered to be in poor general condition; such patients should receive aggressive intervention to avoid worse outcomes.<br />Competing Interests: Conflicts of interest All authors declare that they do not have any conflicts of interests directly associated with the study.<br /> (Copyright © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1437-7780
Volume :
29
Issue :
6
Database :
MEDLINE
Journal :
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Publication Type :
Academic Journal
Accession number :
36871823
Full Text :
https://doi.org/10.1016/j.jiac.2023.02.016